J T Ungerleider, T Andyrsiak, L Fairbanks, G W Ellison, L W Myers
{"title":"Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.","authors":"J T Ungerleider, T Andyrsiak, L Fairbanks, G W Ellison, L W Myers","doi":"10.1300/j251v07n01_04","DOIUrl":null,"url":null,"abstract":"<p><p>Marijuana is reported to decrease spasticity in patients with multiple sclerosis. This is a double blind, placebo controlled, crossover clinical trial of delta-9-THC in 13 subjects with clinical multiple sclerosis and spasticity. Subjects received escalating doses of THC in the range of 2.5-15 mg., five days of THC and five days of placebo in randomized order, divided by a two-day washout period. Subjective ratings of spasticity and side effects were completed and semiquantitative neurological examinations were performed. At doses greater than 7.5 mg there was significant improvement in patient ratings of spasticity compared to placebo. These positive findings in a treatment failure population suggest a role for THC in the treatment of spasticity in multiple sclerosis.</p>","PeriodicalId":77481,"journal":{"name":"Advances in alcohol & substance abuse","volume":"7 1","pages":"39-50"},"PeriodicalIF":0.0000,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1300/j251v07n01_04","citationCount":"167","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in alcohol & substance abuse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1300/j251v07n01_04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 167
Abstract
Marijuana is reported to decrease spasticity in patients with multiple sclerosis. This is a double blind, placebo controlled, crossover clinical trial of delta-9-THC in 13 subjects with clinical multiple sclerosis and spasticity. Subjects received escalating doses of THC in the range of 2.5-15 mg., five days of THC and five days of placebo in randomized order, divided by a two-day washout period. Subjective ratings of spasticity and side effects were completed and semiquantitative neurological examinations were performed. At doses greater than 7.5 mg there was significant improvement in patient ratings of spasticity compared to placebo. These positive findings in a treatment failure population suggest a role for THC in the treatment of spasticity in multiple sclerosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
